Serotonin (5-hydroxytryptamine, 5-HT) and brain-derived neurotrophic factor (BDNF) are two signaling molecules that have important regulatory roles in the development and plasticity of neural circuits that are known to be altered in depression. However, the mechanism by which 5-HT regulates BDNF signaling is unknown. In the present study, we found that 5-HT treatment increases BDNF receptor, TrkB (tropomyosin related kinase B), levels in mouse primary cortical neurons via a Rac1 (RAS-related C3 botulinum toxin substrate 1)-dependent mechanism. Significant increases in the levels of type-2 transglutaminase (TG2, which is implicated in transamidation of 5-HT to Rac1) are observed in the mouse prefrontal cortex (PFC) following chronic exposure to stress. We also found that TG2 levels are increased in the post-mortem PFC of depressed suicide subjects relative to matched controls. Moreover, in mice, neuronal overexpression of TG2 resulted in the atrophy of neurons and reduced levels of TrkB in the PFC as well as a depressive-like phenotype. Overexpression of TG2 in mouse cortical neurons reduced TrkB levels as a result of impaired endocytosis of TrkB. TG2 inhibition by either a viral particle or pharmacological approach attenuated behavioral deficits caused by chronic unpredictable stress. Moreover, the overexpression of TrkB in the mouse PFC ameliorated the depressive-like phenotype of TG2-overexpressed mice. Taken together, these post-mortem and preclinical findings identify TG2 as a critical mediator of the altered TrkB expression and depressive-like behaviors associated with chronic exposure to stress and suggest that TG2 may represent a novel therapeutic target in depression. 
INTRODUCTION
Major depression is one of the most prevalent and debilitating illnesses worldwide causing an enormous personal and economic burden. Although the therapeutic options for this disorder have been improved over time, it is sobering that depression is still characterized by persistent functional impairments for most patients. Chronic stress is known to contribute to the pathophysiology of depression, and exposure to chronic or repeated stress leads to synaptic changes and depressive-like behaviors in rodents. Moreover, chronic stress-induced depressive behaviors are strongly linked to alterations in serotonin (5-hydroxytryptamine, 5-HT) and brain-derived neurotrophic factor (BDNF), two signaling molecules that have regulatory roles in many neuronal functions including neurogenesis, behavior and synaptic plasticity. In addition, a large body of evidence indicates alterations in 5-HT and BDNF signaling pathways in the brain of depressed subjects. Studies also suggest that serotonergic transmission exerts powerful control over BDNF signaling, and enhanced serotonergic transmission may be a key mechanism underlying the therapeutic effects of antidepressants. 1 However, the mechanisms underlying the interactions between 5-HT and BDNF signaling pathways and their relevance to depression are poorly understood.
Recent studies have shown the transamidation of 5-HT to small GTPases such as RhoA and Rac1, via a process catalyzed by enzymes called transglutaminases (TGs). 2, 3 TGs are a family of calcium (Ca2+) dependent enzymes that catalyze the formation of intra-and intermolecular bonds between the γ-carboxyamide moiety of glutamine and primary amino groups. 4 Type-2 transglutaminase (TG2), the most ubiquitous TG isoform, is involved in neural development and functioning. 5 A number of studies have shown that transamidated small GTPases such as Rac1 and RhoA are constitutively active and that they undergo rapid proteasomal degradation. 2, 3, 6 Therefore, increased transamidation results in less 5-HT availability for downstream signaling, a process that has been implicated in the pathophysiology of depression. In the current study, we found that TG2 levels are increased in the prefrontal cortex (PFC) of both chronic stressexposed mice and of depressed suicide subjects. TG2 overexpression in mice resulted in the atrophy of neurons and reduced levels of BDNF receptor, tropomyosin related kinase B (TrkB), in the PFC as well as a depressive-like phenotype. Moreover, overexpression of TrkB in the mouse PFC ameliorated the depressive-like phenotype of TG2-overexpressed mice.
and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA) 7 and the colony was maintained in our animal housing facility at the Augusta University (Augusta, GA, USA). Mice were housed in groups of four mice in standard polypropylene cages in 12-h light-dark cycle in compliance with the US National Institute of Health guidelines and approved by the Augusta University animal welfare guidelines. An 8-10-week-old male mice were used for the in vivo experiments. Mice were assigned to experimental groups based on their genotype. Selection of animal for lentiviral or pharmacological treatment was performed randomly and in a blinded manner.
Cell culture
Primary cortical neurons were prepared at E16. Neurons were cultured in Neurobasal medium containing B27 supplement, 10% fetal bovine serum, penicillin/streptomycin mixture of antibiotics and glutamax for 5 days. Media were changed with fresh media before the experimental treatment. Treatments were performed in neurons at day in vitro 5-7. Drugs NSC 23766 (NSC, Tocris, Ellisville, MO, USA) and fluoxetine (Sigma, St Louis, MO, USA) were administered intraperitoneally (100 μl) at a concentration of 2.5 mg per kg body weight per day (mg kg − 1 per day) and 20 mg kg
per day, respectively. Cysteamine (Sigma) was administered at a concentration of 150 mg kg − 1 per day through drinking water for 21 days. Corticosterone (4-pregnen-11b-diol-3 20-dione 21-hemisuccinate; Sigma) was dissolved in vehicle (0.45% hydroxypropyl-β-cyclodextrin, Sigma). Corticosterone (35 μg ml − 1 , equivalent to 5 mg kg − 1 per day) was delivered ad libitum in the drinking water. The dose and duration of corticosterone treatment in mice were selected based on earlier studies, 8, 9 where the above dose and duration of treatment with CORT induced anxiety and depressivelike behaviors in mice. The fluid intake was monitored throughout the treatment period and the corticosterone dose was adjusted accordingly. Primary cortical neurons were treated with 5-HT (Sigma) at a concentration of 5-100 μM at day in vitro 5-7. In glucocorticoid receptor inhibitor studies, cells were treated with RU486 (1 μM; Sigma) 30 min before 48-h corticosterone (1 μM; Sigma) treatment. Neurons were treated with BDNF (ProsPec, Rehovot, Israel) at 100ng ml − 1 for indicated time period.
Mouse genotyping TG2+/+ mice were bred on C57BL/6J backgrounds and their offspring were genotyped by PCR of ear punch DNA (DNeasy Kits; Qiagen, Valencia, CA, USA). PCR reaction was performed over 35 cycles using GoTaq Green Master Mix (Promega, Madison, WI, USA). Primers used were as follows: (i) PrP-sense primer, 5′-GCTGAAGCATTCTGCCTTCCTAGTG-3′ and an antisense primer, 5′-GTGGATACCCCCTCCCCCAGCCTAGACC-3′.
(ii) htTGsense primer, 5′-CTCGTGGAGCCAGTTATCAACAG-3′ and antisense primer, 5′-TGAGGACATACTCCTGCCGCTCCTCTTCCGAGG-3′. Annealing temperature was set at 60°C. The products of the PCR reaction were visualized using agarose gel electrophoresis.
Stereotaxic injection of lentivirus
DNA for pCAG-TrkB-EF1a-copGFP (p289) and the matching control, pCDH-CAG-eGFP-EF1a-copGFP (p375), were kindly provided by Mark H Tuszynski, (University of California, San Diego, CA, USA) and lentiviral particles were synthesized by Applied Biological Materials, Richmond, BC, Canada pLenti-GIII-CMV-mTGM2-GFP-2A-Puro, pLenti-CMV-GFP-2A-Puro-Blank vector, lentiviral vector expressing TG2 siRNA and scrambled siRNA GFP were purchased from Applied Biological Materials. Lentiviral particles were injected stereotaxically into mouse PFC. In brief, mice received buprenorphine (0.05 mg kg − 1 , subcutaneously) for 15 min and then anesthetized with 1.5-2.5% isoflourane mixed with oxygen in an induction chamber. Mice were maintained under deep anesthesia and mounted in a stereotaxic apparatus. Approximately 1 mm size burr hole were made to perform a very small craniotomy on the right side as per the recommended coordinates 10 (x = 0.5 mm (lateral), y = 1.0 mm (anterior-posterior), with respect to bregma at 0), z = 1.0 mm (dorsoventral with brain surface at 0). A 30-gauge needle attached to a microsyringe containing lentivirus were inserted and lowered into the prefrontal cortical region of the brain. The microsyringe was left in place 5 min after each injection, and a total volume of 1.0 μl (1 × 10 9 infectious particles per milliliter) of lentivirus was administered at a rate of 0.2 μl min − 1 at each site (Stoelting, Wood Dale, IL, USA). Mice will be allowed to recover from anesthesia and transferred to a clean cage with free access to chow diet and water. After the 2 weeks of injection, the injection site was confirmed by ex vivo imaging analysis for the fluorescence of lentiviral particles.
CUS procedure
CUS experiments were performed according to previously published procedure with modifications. 11 Three weeks before the beginning of the CUS paradigm, all animals were individually housed, while all other aspects of housing remained as standard housing conditions. The details of each stressor, duration of stress exposure and sequence of exposure is shown in Supplementary Table 3 . The stress exposure regimen was mixed with the qualifier that exposures to the same stressor never occurred consecutively within a day. The controls received the same temporal and spatial sequence of habituation and test days that the stressed animals experienced.
Sucrose preference test
Mice were habituated to 1% sucrose solution for 3 days at the start of the experiment, in which two bottles of 1% sucrose solution were placed in each cage. After adaptation, mice were deprived of fluid for 16 h. Mice were then presented with two identical bottles of 1% sucrose and water for 24 h. The position of the bottles containing water or sucrose solution was switched halfway through the test. At the end of the 24-h test, sucrose and water consumption (ml) were measured, and the preference for sucrose was calculated as a percentage of consumed sucrose solution of the total amount of liquid drunk.
Forced swim test
Mice were subjected to one 5-min session of swimming in water. On the test day, mice were placed in a clear cylinder with water (24 ± 1°C, 45-cm depth). The sessions were recorded from the side, and the immobility time was scored by a blind observer. Immobility was calculated as the least amount of movement of experimental mice to stay afloat.
Tail suspension test
Each mouse was suspended with a tape 0.75 cm away from their tails and elevated 70 cm above the floor. Behavior was recorded for 6 min. Observer blinded to the subject's treatment group scored video recordings for time spent struggling or immobile.
Y-maze test
The Y-maze was opaque white-cast acrylic with three arms (each = 30 cm L × 8 cm W × 6 cm H) joined at one end to form a 'Y' shape with a common central zone. Each trial was initiated by releasing a mouse into the center zone for a 10-min free exploration period. Extramaze, but not intramaze, cues were visible to use as spatial landmarks. The apparatus was cleaned with 50% ethanol between trials. All trials were video-recorded (30 frames s − 1 ; Basler GigE ace camera, Basler, Ahrensburg, Germany) to manually score the sequence that each mouse entered arms (in 1-min bins) over the testing period. Subsequently, the first two trials were omitted and the total number of alternations (entries into three different arms consecutively) and arm entries were counted. The percent alternation was calculated, as follows: ((number of alternations)/(total possible alternations)) × 100%.
Open field test
Mice activity in an open field was measured over a 10-min period.
12 Time spent (s) in margin and center, total distance (cm) and mean speed (cm s − 1 ) were measured during the session. Ethovision XT 10 (Noldus Information Technologies, Leesburg, VA, USA) software and open field chamber (40 cm × 40 cm × 40 cm), and a video camera was fixed over the chamber by an adjacent rod, an activity monitor, a programmer and a printer were used for analysis. Sessions total for all parameters were taken. Observations were recorded for 10 min.
PPI test
On the first day, mice were allowed to habituate to the testing chamber apparatus (San Diego Instruments, San Diego, CA, USA) for 20 min. The second day consisted of the mice being exposed to various decibels (dB) of auditory stimuli, randomized for a total of 24 trials to acclimate the mice to the startle and prepulse stimuli. The third day, the mice underwent testing for a total of 60 pseudorandomized trials. These trials were set up such that no prepulse amplitude repeated itself consecutively or have the three prepulse stimuli in consecutive order (i.e., 75, 80 and 85 dB). A continuous background noise of 70 dB was used. The nulstim background noise was 70 dB with a duration of 40 ms. Prepulse values were 75, 80 and 85 dB at 20 ms durations. Startle amplitude of 120 dB at 40 ms was used. The interstimulus interval between the prepulse/startle presentations ranged from 10 to 30 s and the total experimental session lasted about 23 min.
Light-dark preference test
In this test, the mouse open field activity monitors were fitted with dark box inserts, which are opaque to visible light) to cover one-half of the open field area and thus separating the apparatus into two zones of equal area (i.e., a brightly lit zone and a darkened zone). Desk lamps located above the activity monitors were used to provide an illumination level of~1000 lx in the brightly lit zone, whereas the illumination level in the darkened zone was~5 lx. The time spent and distance traveled in the light and dark zones of the apparatus were recorded for the 10 min test session.
Elevated plus maze
The elevated plus maze consisted of two orthogonal closed 
Western blotting
Animals were killed by cervical dislocation, and the PFC, hippocampus and striatum samples were collected according to a mouse brain atlas. 13 Brain tissues and primary cortical neuronal cells were lysed in ice-cold lysis buffer.
14 Protein was electrophoretically separated on a sodium dodecylsulfate polyacrylamide gel electrophoresis gel and transferred to a nitrocellulose membrane. Blots were incubated in the appropriate primary antibody specific for TG2 (Cell Signaling; 3557; 1:1000); TrkB (Cell Signaling, Danvers, MA, USA; 4603; 1:1000); pTrkB (1:1000, kindly gifted by Dr Chao, New York University School of Medicine, New York, NY, USA); 15 pERK (Thr202/Tyr204; Cell Signaling; 4370; 1:1000); ERK (Cell Signaling; 9102; 1:1000); pAkt (Ser473; Cell Signaling; 9018; 1:1000); Akt (Cell Signaling; 9272; 1:1000); β-actin (Sigma; A4700; 1:20 000); Rac1 (Santa Cruz Biotech, Santa Cruz, CA, USA; SC-95; 1:500) and developed with the ECL Plus Western Blotting Detection System (GE Healthcare, Piscataway, NJ, USA). Optical densities of the bands were analyzed using ImageJ software (NIH, Bethesda, MD, USA). For analysis, protein levels were normalized to β-actin levels and then expressed as a fold change of that in control animals. For figure panels, contrasts have been adjusted linearly for easier viewing of bands.
Quantitative reverse transcriptase-PCR RNA was purified using a commercially available kit (SV RNA Isolation; Promega), quantitative reverse transcriptase-PCR was performed on a MasterCycler (Eppendorf, Westburg, NY, USA) using a SuperScript III Platinum SYBR Green One-Step Quantitative Reverse Transcriptase-PCR Kit (Invitrogen, Carlsbad, CA, USA). Primers for TG2 were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Primers used were: forward, 5'-TCAACTGCAACGATGACCAGG-3' and reverse, 5'-TGTTCTGGTCAT GGGCCG-3'. Ct values of TG2 were normalized to that of housekeeping gene (β-actin).
Immunofluorescence staining of cultured neurons
For immunofluorescence staining of primary cortical neurons, cultured neurons were transfected with control or TG2 lentiviral particles using Effectene Transfection Reagent (Qiagen) 48 h before BDNF (100 ng ml − 1 ) treatment. Cells were washed and permeabilized for 5 min with 0.2% (v v − 1 ) Triton X-100 and blocked for 1 h at room temperature with 5% normal donkey serum. Anti-TrkB (Abcam, Cambridge, MA, USA; ab52191; 1:1000) and anti-Lamp1 (DSHB (1D4B); 1:500) staining was performed overnight at 4°C, followed by rinsing with phosphate-buffered saline and incubation for 1 h at room temperature with Cy2-and Cy3-conjugated secondary antibodies (Jackson Immunoresearch Laboratories, West Grove, PA, USA). Cells were then washed and mounted using ProLong Gold Antifade Mountant containing DAPI (4',6-diamidino-2-phenylindole) (Molecular Probes, Eugene, OR, USA). Confocal images were obtained using a Zeiss LSM 510 META confocal microscope. Pictures were taken under a × 40 Plan-Apochromat objective.
High-performance liquid chromatography
Trunk blood samples were collected into microcentrifuge tubes containing ACD anticoagulant solution A (BD Biosciences, San Jose, CA, USA). Biogenic amines in trunk blood and brain samples were determined by a specific high-performance liquid chromatography assay using a Decade (oxidation, 0.7) electrochemical detector (Antec, Leiden, the Netherlands). Biogenic amines were eluted with a mobile phase consisting of 89.5% of 0. 
Immunohistochemistry
Mice were anesthetized and transcardially perfused with phosphatebuffered saline, followed by 4% paraformaldehyde in PBS. Brains were removed and PFC cryostat sections (10 mm thick, coronal sections) were prepared with standard protocols. For immunostaining, the brain section was reacted with anti-TG2 (Abcam; ab421; 1:300) and anti-PV (Swant, Bellinzona, Switzerland; 235; 1:500) or anti-CAMKII (BD Transduction Lab., Lexington, KY, USA; 611292; 1:500), followed by Cy2-and Cy3-conjugated secondary antibodies. Sections were mount with antifade mountant containing DAPI and images were taken using confocal microscope under × 40 objective. 3,3'-Diaminobenzidine (DAB) staining was carried out using the ABC Kit, followed by the Elite DAB Staining Kit, according to the manufacturer's instructions (Vector Laboratories, Burlingame, CA, USA).
Spine analysis
Golgi staining was carried out using the FD Rapid Golgi Stain Kit (FD Neurotechnologies, Baltimore, MD, USA). 16 In brief, the mouse brains were placed in an appropriate impregnation solution and stored in the dark for 2 weeks at room temperature. Next, the brains were transferred to a second impregnation solution and incubated for 3 days at 4°C. Finally, semihorizontal sections (120 μm) were prepared with an oscillating tissue slicer (Leica, VT1000; Leica, Wetzlar, Germany). Sections were stained and then mounted on gelatin-coated slides. Slides were then rinsed again in distilled water and dehydrated in absolute alcohol, cleared with xylene, mounted on slides and covered with nonacidic synthetic balsam and coverslips.
Post-mortem samples
Human post-mortem brain tissue samples (Brodmann's area 10) from suicide completers (N = 14) and psychiatrically normal controls (N = 14) were used in the current study. The samples were obtained from the Quebec Suicide Brain Bank (Douglas Institute, Montréal, QC, Canada; www. douglas.qc.ca/suicide). The study was granted by the Douglas Hospital Institutional Review Board and written informed consent was obtained from each participating family (Declaration of Helsinki, 1964) . A description of the Quebec Suicide Brain Bank and other detailed demographics and samples' quality were published earlier. 17, 18 Statistical analysis No statistical methods were used to predetermine sample sizes in mouse studies, but our sample sizes are similar to those reported in previous publications. 8, 9, 19 For mouse studies, data were analyzed using two-tailed Student's t-tests (for two-group comparisons) or ANOVA (for multiplegroup comparisons). P o0.05 was considered significant. Post hoc analyses were carried out using Bonferroni's test. For post-mortem studies, analysis of covariance was used to examine differences in TG2 mRNA between post-mortem samples of depressed suicide subjects and the controls (Affection Status). Group differences in TG2 mRNA were examined with age, post-mortem interval, pH, RNA integrity, substance use at death and psychiatric medication use evaluated for inclusion as possible covariates. Only covariates with at least small associations-correlations of 0.20 and higher-with TG2 were considered for inclusion in the analysis of covariance model. Candidate covariates that were significantly correlated with TG2 mRNA were included in the model. Exact probability (P) values of o5% were flagged as statistically significant. Cohen d was computed as a measure of effect size difference. All analyses were performed using SPSS Statistics 20 software (IBM, Armonk, NY, USA). (Figures 1a and b) . To examine the possibility that Rac1 could influence the expression of TrkB, we performed in vitro transfection assays in primary cortical neurons. Rac1 pull-down experiments showed that constitutively active Rac1 constructs had more active GTPases compared with control constructs (P o0.05) (Figure 1c ). TrkB protein levels were significantly higher in cells transfected with constitutively active Rac1 constructs as compared with wild-type (WT) cells (P o0.05) (Figure 1c) . Next, we examined whether pharmacological inhibition of Rac1 activity could influence the 5-HT-induced increase in TrkB protein levels. Pre-treatment with NSC 23766, a Rac1 inhibitor attenuated the 5-HT-stimulated increase in TrkB protein levels in neurons (P o 0.05) (Figure 1d) .
RESULTS

Rac1 is involved in
We next performed in vivo experiments. Mice administered NSC 23766 for 2 weeks showed depressive-like behaviors (i.e., increases in the time spent immobile) in the tail suspension test (TST) (P o 0.05) (Supplementary Figure 1a) and the forced swim test (FST) (Po 0.05) (Supplementary Figure 1b) . Figure 1c) , indicating that our conclusions about depressive-like behaviors were not confounded by decreases in motor function/ locomotor activity or elevated anxiety-like behaviors. NSC 23766 treatment significantly inhibited phosphorylation of TrkB in the mouse PFC (P o0.05) (Supplementary Figures 1d and e) . Furthermore, decreases in the levels of the phosphorylation of Akt (P o0.05) (Supplementary Figures 1d and f) and ERK (P o0.05) (Supplementary Figures 1d and g ) (i.e., two molecules that are activated in TrkB-mediated pathways) were found in the PFC of mice following Rac1 inhibition.
TG2 overexpression induces reductions in TrkB and Rac1 protein levels in mouse PFC 5-HT has been shown to transamidate Rac1 leading to its proteasomal degradation. 2 To understand the mechanism linking 5-HT to TrkB, we used mice overexpressing TG2 (hereafter called TG2 mice), the enzyme responsible for the above transmidation process. It has been shown that TG2 is expressed predominantly in the brain of TG2 mice. 7 We found that TG2 overexpression in male mice resulted in higher TG2 protein expression in the PFC, hippocampus and striatum (Figure 2a) . We performed immunofluorescence studies in cortical sections from TG2 mice to examine the cellular localization of TG2. Laser confocal imaging showed that TG2 is selectively colocalized with CamKII+ cells (Supplementary Figure 2a) , not with PV+ cells (Supplementary  Figure 2b) . Studies using vGlut1 antibody further confirmed the localization of TG2 in pyramidal neurons ( Supplementary  Figure 2c) . Rac1 protein levels were significantly lower in the PFC of male TG2 mice (P o 0.05) (Figure 2b ) as compared with WT littermate controls. We did not find any significant change in Rac1 protein levels in the hippocampus (Supplementary Figure 3a) and striatum ( Supplementary Figure 3b) of TG2 mice, indicating cortex-specific changes in Rac1 expression in TG2 mice. Also, TG2 overexpression did not cause any change in the levels of RhoA (another small GTPase) in any of the brain regions studied (Supplementary Figures 3c-e) . As we found a significant reduction in Rac1 protein levels in PFC of TG2 mice and Rac1 is known to be involved in the endocytosis of TrkB, 20 we next examined TrkB protein levels in WT and TG2 mice. TG2 overexpression reduced the levels of both TrkB (P o 0.05) (Figure 2c ) and its phosphorylated form (pTrkB) (P o 0.05) (Figure 2d ) in the mouse PFC, but no significant change was observed in the hippocampus (Supplementary Figure 3f) or striatum (Supplementary Figure 3g) . In addition, we found significant decreases in the phosphorylation of Akt (Po 0.05) (Figure 2e ) and ERK (P o 0.05) (Figure 2f ) in the PFC of TG2 mice. Because recent studies have implicated other neurotrophic factors such as nerve growth factor and vascular endothelial growth factor in neuropsychiatric disorders, we next examined the levels of NGF receptor, TrkA, and vascular endothelial growth factor receptor, Flk1, in WT and TG2 mice. No significant change was found in the levels of TrkA (Supplementary Figure 3h) and Flk1 (Supplementary Figure 3i) in PFC of TG2 mice as compared with WT mice. To determine whether TG2 overexpression in mice causes any change in spine density, Golgi staining was performed. Spines were counted on secondary and tertiary branches of apical dendrites in the superficial layer and deep layers. As shown in Figure 2g , spine density was reduced in layer V of PFC in TG2 mice, compared with control littermates.
TG2 overexpression induces depressive-like behavior in mice Next, we performed behavioral assays related to schizophrenia, anxiety and depression in WT and TG2 mice. In the Prepulse inhibition (PPI) test (a sensorimotor gating assessment), we used a combination of auditory-evoked startle (120 dB) and three prepulse levels (75, 80 and 85 dB). PPI scores were analyzed using two-way analysis of variance (ANOVA) with prepulse intensities as a within-subject factor, and genotype as between-subject factor. We found a significant main effect of prepulse intensity (F(2,36) = 28.39; P o 0.0001) and genotype (F(1,36) = 6.578; P = 0.0146); however, the genotype × prepulse intensity interaction was not significant. Post hoc analyses indicated that the %PPI increased with increasing prepulse intensity (P o 0.05 for the 75 and 80 dB level versus the 70 dB level) in both WT and TG2-overexpressed mice. Although the %PPI at the 75 dB level was slightly higher in the TG2-overexpressed mice as compared with WT mice, there were no major differences in PPI between the genotypes (Supplementary Figure 4a) . Data on startle amplitude showed no significant difference between WT and TG2 mice (Supplementary Figure 4a) . There were also no significant differences in spatial alternation in the Y-maze between TG2 and WT mice (Supplementary Figure 4b) , indicating that spatial working memory performance was similar in the two genotypes. Interestingly, we did observe fewer arm entries in the TG2 mice, and visual observation of the videos indicated a considerable amount of stretch and attend behaviors in these mice, potentially indicative of an anxiety-like phenotype. However, more rigorous evaluations of anxiety-like behaviors in the elevated plus maze test (Supplementary Figure 4c) , light-dark test (Supplementary Figure 4d) and open field (Figure 2h ) did not reveal any significant differences between TG2 and WT mice. We did, however, observe larger distances traveled in the open field chamber suggestive of hyperactivity in TG2 mice as compared with WT mice (P o0.05) (Figure 2h ). TG2 and WT mice were also tested in the TST and FST for depressive-like behaviors. TG2 mice were immobile for a longer period of time comapred with WT mice in the TST (P o 0.05) and FST (P o0.05), indicating a depressive-like phenotype in these mice (Figure 2h) . Moreover, TG2 overexpression resulted in a significant decrease in sucrose preference, suggestive of an anhedonia-like phenotype in these mice (Figure 2h ).
To determine whether TG2 overexpression results in alterations in 5-HT levels, we examined 5-HT levels in the PFC and hippocampus of WT and TG2 mice. No significant change in 5-HT levels was found in the above brain regions ( Supplementary  Figures 5a and b) . However, significantly higher 5-HT levels were observed in whole blood of TG2 mice as compared with the WT mice (P o 0.05) (Figure 2i) . Furthermore, acute injection of the 5-HT reuptake inhibitor (antidepressant), fluoxetine (20 mg kg − 1 ), significantly attenuated the hyperactivity in TG2 mice (P o0.05) (Supplementary Figure 6a) . Moreover, fluoxetine significantly increased mobility of TG2 mice in the TST (P o0.05) (Supplementary Figure 6b) and FST (P o0.05) (Supplementary  Figure 6c) . We found that fluoxetine administration also increased TrkB phosphorylation in the PFC in both WT and TG2 mice (P o 0.05) (Supplementary Figure 6d) . PFC-specific overexpression of TG2 induces depressive-like behavior in mice Since the changes in Rac1 and TrkB were specific to the PFC of TG2 mice, we investigated whether PFC-specific overexpression of TG2 induces a depressive-like phenotype in mice (Figure 2j ). After stereotaxic lentiviral TG2 gene delivery to the PFC, TG2-GFP was detected in the PFC by immunofluorescence imaging and TG2 immunohistochemistry (Figure 2k ). TG2 protein levels were higher in the PFC samples from lentiviral TG2-injected mice as compared with lentiviral-GFP-injected control mice (P o 0.05) (Figure 2l) . Moreover, TG2 overexpression induced a significant reduction in TrkB protein levels in the PFC (P o0.05) (Figure 2l ). Behavioral analysis at 2 weeks after lentiviral transduction showed that lentiviral TG2-injected mice exhibited hyperactivity in the open field test (P o0.05), and depressive-like behaviors in the TST (P o 0.05) and FST (P o0.05) (Figure 2m ).
Glucocorticoid receptor mediates stress-induced increase in TG2 levels As changes in hypothalamic-pituitary-adrenal axis and, therefore, glucocorticoid levels are implicated in stress pathophysiology, we examined whether TG2 levels are affected in mice following chronic glucocorticoid exposure. Chronic corticosterone treatment has been shown to induce a depressive-like phenotype and a decrease in TrkB protein levels in mouse PFC. 8 We did not find any significant change in fluid consumption rate in mice following corticosterone administration for 7 weeks (Supplementary Figure 7) . A significant increase in TG2 protein levels was observed in the PFC of mice following corticosterone exposure (P o0.05) (Supplementary Figure 8a) . In addition, corticosterone-induced increase in TG2 levels was inhibited by RU486, a glucocorticoid receptor antagonist in primary cortical neurons, suggesting that glucocorticoid signaling is involved in the increase in TG2 levels following stress (P o 0.05) (Supplementary Figure 8b) . TG2 mediates the CUS-induced changes in depressive-like behavior and TrkB protein levels in mice Next, we examined whether TG2 is involved in chronic stress-induced depressive-like behavior in mice. We used a chronic unpredictable stress (CUS) procedure, which is a wellcharacterized (and predictive) paradigm for producing depressivelike signs in rodents. We found a significant increase in TG2 protein levels in the PFC of mice exposed to CUS for 21 days (P o 0.05) (Figure 3a) . To determine the direct role of TG2 in CUSinduced depressive-like behavior, we silenced TG2 expression in mouse PFC using lentiviral vectors expressing TG2 small interfering RNA (siRNA) (Figure 3b) . A significant reduction in TG2 protein levels was observed in mouse PFC following TG2 siRNA administration (Figure 3c ). We found that CUS induced depressive-like behavior (i.e., increased immobility time in TST and FST) in WT mice, but not in TG2 siRNA-injected mice (Po 0.05) (Figure 3d) . Moreover, CUS exposure resulted in decreased TrkB protein levels in the PFC of WT mice, but not in TG2 siRNA-injected mice (Figure 3e ). The idea that TG2 is responsible for the behavioral effects of CUS was further confirmed using cysteamine, a pharmacological inhibitor of TG2 (Figure 3f ). Cysteamine treatment for 21 days significantly attenuated the CUS-induced increase in immobility time in TST (P o 0.05) and FST (P o0.05) in mice (Figure 3g ). No significant difference was observed in open field activity in mice following CUS (P o0.05) (Figure 3g ). These results demonstrate that TG2 mediates stress-induced depressivelike behaviors and decreases in TrkB levels in mice.
Overexpression of TrkB in the PFC of TG2-overexpressed mice ameliorates their depressive-like behaviors If the reduced levels of TrkB in the PFC of TG2 mice mediate the depressive-like phenotype, overexpression of TrkB should ameliorate the behavioral signs. We performed stereotaxic injection of lentiviral TrkB into the PFC of WT and TG2 mice (Figure 4a ). TrkB expression was confirmed by immunofluorescence and immunohistochemistry (Figure 4b) . Also, we found increased levels of TrkB in the PFC samples from lentiviral TrkB-injected mice as compared with lentiviral-GFP-injected control mice (P o 0.05) (Figure 4c ). In the behavioral tests, the hyperactivity (i.e., increase in distance traveled in the open field test) of TG2 mice was significantly reduced following TrkB overexpression into the PFC (P o 0.05) (Figure 4d ). In addition, lentiviral TrkB overexpression significantly reduced the immobility of TG2 mice in TST (P o 0.05) and FST (P o 0.05) (Figure 4d ). These results strongly suggest that reduced TrkB signaling is involved in the depressive-like behaviors observed in TG2 mice. It is known that Trk receptors are recycled to the plasma membrane via recycling endosomes or transported from early to late endosomes and eventually to lysosomes for degradation. As we found a significant reduction in TrkB protein levels in TG2 mice, we next examined whether the degradation of TrkB is higher when TG2 is overexpressed in primary cortical neurons with lentiviral particles. The half-life of TrkB was examined following BDNF treatment by measuring the ratios of TrkB at different time intervals to TrkB levels before BDNF treatment. Our data indicated that TrkB is more rapidly degraded in TG2-overexpressed neurons (Supplementary Figure 9a) . To track the intracellular localization of TrkB receptors, co-immunofluorescence was performed with the lysosomal marker, LAMP1. Under BDNF induction, TrkB was more localized to LAMP1 in the TG2-overexpressing neurons compared with the neurons treated with control lentiviral particles, suggesting that LAMP1 vesicles initiate the lysosomal degradation (Supplementary Figure 9b) .
Increases in TG2 mRNA and protein levels are detected in the PFC of depressed suicide subjects To determine the importance of TG2 in depressive disorders in humans, we examined post-mortem brain samples of depressed suicide subjects and nonsuicide controls. The post-mortem samples comprised 28 men, half of whom were suicide completers who had been diagnosed with major depressive disorder. None of the evaluated covariates had a significant association with TG2 mRNA. RNA integrity (r = 0.248, P = 0.20) and medication use (r = 0.303, P = 0.12) had small associations with TG2 mRNA and thus these covariates were included in the analysis of covariance model (Supplementary Tables 1 and 2 Figure 10a) . Also, we found a significant increase in TG2 protein levels in the PFC of depressed suicide subjects as compared with control subjects (Supplementary Figures 10b and c) . In addition, a significant reduction in Rac1 protein levels ( Supplementary  Figure 10b and d) was observed in the depressed suicide subjects.
DISCUSSION
Collectively, the data we have presented in this report clearly suggest that TG2 is involved in depressive-like behaviors. TG2 has been shown to transamidate 5-HT to Rac1, leading to the transient activation and proteasomal degradation of Rac1. 2 We found a significant reduction in Rac1 levels in the PFC of TG2-overexpressed mice. Rac1 has an important role in neuronal development, axon guidance, dendritic spine morphogenesis and maintenance, and in learning and memory processes. 21, 22 Moreover, chronic stress has been shown to reduce Rac1 expression in rodents, and a significant reduction in Rac1 expression has been observed in the nucleus accumbens of depressed subjects. 23 Our data show a significant reduction in Rac1 expression in the PFC of depressed subjects, further suggesting that this GTPase has an important role in the pathophysiology of depression. Furthermore, Rac1 has been shown to mediate the endocytosis of TrkB in neurons. 20 Interestingly, the behavioral deficits in TG2-overexpressed mice were ameliorated by overexpression of TrkB in the PFC and by antidepressant drug that can increase TrkB signaling, suggesting that impaired TrkB signaling might contribute to the depressivelike behaviors observed in TG2 mice.
Despite the above evidence that TG2 has a pivotal role in depression, questions still remain as to how stress induces increases in TG2 expression. TG2 is a direct transcriptional target of nuclear factor-κB (NF-κB) and the TG2 gene contains two consensus NF-κB binding sites. 24 Activation of NF-κB has been shown to induce TG2 expression, and the NF-κB subunit RelA is both necessary and sufficient to drive TG2 expression. 25 Chronic stress and/or inflammation are known to activate NF-κB signaling and this signaling pathway is required for the depressive-like behavior in rodents caused by exposure to chronic stress. 19 In the present study, we evaluated depressive-like behaviors in mice using the TST and FST. Although the FST was originally developed as a model for assessing antidepressant-like activity in rats, 26 ,27 a number of recent studies have used this test for examining stress-induced depressive-like behavior in mice. 28 While the FST is sensitive to all of the effective antidepressant drug classes (and is currently the most widely used model for evaluating potential antidepressant drugs), its validity as a true measure of depression-like behavior and antidepressant activity of drugs has been debated owing to potential confounding effects of altered locomotor activity. 29, 30 Therefore, we performed locomotor activity assessments (open field test) along with the FST in our studies to determine whether the changes in immobility in the FST might be related to alterations in the general activity of the mice. It has been suggested that an increase in active behaviors in the FST coupled with a reduction in locomotor activity following acute antidepressant treatment validates the behavior in FST. 31 We found similar changes in the open field test and FST in TG2 mice following fluoxetine treatment. Although we observed significant changes in depressive-like behavior following acute fluoxetine treatment in mice, chronic administration of antidepressants is generally required to achieve a positive effect (with a delayed onset of action) on the Hamilton Depression Rating Scale (HAM-D) score in humans. The acute activation of TrkB in cortex after antidepressant administration is expected to lead to plastic changes in synaptic function and neuronal connectivity as TrkB signaling is known to stimulate outgrowth and regeneration of dendrites and axons [32] [33] [34] and to promote synaptogenesis. 34 It is possible that post-translational modifications of proteins involved in neuronal functions with acute antidepressant treatment results in changes in some behaviors and symptoms, whereas changes at the gene level following chronic administration underlies the more lasting therapeutic and prophylactic properties of antidepressants (i.e., effects associated with neurogenesis and long-term changes in neuroplasticity). Such a slow development of neuronal changes might also explain, in part, the delayed onset of action of antidepressants in humans.
It is also important to note that the phenotypic alterations induced by the overexpression of TG2 in mice appeared to be relatively selective for depression and anhedonia-related behaviors as opposed to anxiety, schizophrenia-related signs. This argument is supported by the observation that (other than hyperactivity observed in the locomotor assessments) few notable effects were observed in the anxiety-related tests (elevated plus maze and light-dark box), sensorimotor gating task (PPI) or working/short-term memory task (Y-maze spontaneous alternation).
In conclusion, in this manuscript we have presented multiple lines of evidence (i.e., from neuronal culture experiments, behavioral and molecular studies in transgenic mice, and analyses of post-mortem samples from depressed subjects) to support the argument that the TG enzyme TG2 contributes to the pathophysiology and symptoms of depression. Moreover, the reversal of chronic stress-induced behavioral deficits by cysteamine (a pharmacological inhibitor of TG2) in mice suggests that TG2 may represent a novel therapeutic target in depression.
